Pfizer (NYSE:PFE) Shares Up 1.1% – Should You Buy?

Pfizer Inc. (NYSE:PFE) shares were up 1.1% on Tuesday . The company traded as high as $28.31 and last traded at $28.08. Approximately 43,326,725 shares were traded during trading, a decline of 6% from the average daily volume of 45,945,676 shares. The stock had previously closed at $27.77.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court orders Poland and Romania to accept €1.9B ($2.2B) of Pfizer COVID-19 vaccines — a legal win that secures material near-term revenue/cash collection for vaccine inventory. Article Title
• Positive Sentiment: Technical and momentum support: PFE has traded above its 50- and 200-day SMAs for months and has outperformed the market recently, which can attract trend-focused buyers. Article Title
• Neutral Sentiment: Corporate reshaping: Pfizer is exiting its ViiV HIV joint-venture stake as GSK and Shionogi reshuffle ownership — could free capital or shift long-term HIV exposure; impact depends on how proceeds are deployed. Article Title
• Neutral Sentiment: Valuation vs. growth: Analysts note a rebound in the share price but flag a mixed growth outlook — valuation may be stretched if revenue momentum slows, keeping upside limited absent clearer pipeline/organic growth signals. Article Title
• Negative Sentiment: Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID vaccine in 50–64-year-olds due to low enrollment — a sign of weak demand that could limit future vaccine revenue and reduce the near-term growth runway. Article Title
• Negative Sentiment: Bearish takes highlight that a large dividend may not compensate for underlying growth issues — narratives around slowing top-line growth and dependence on legacy products pressure longer-term upside. Article Title
• Negative Sentiment: Cost and footprint moves: reports that Pfizer will close its South San Francisco research site may trim expenses but also reduce R&D capacity, which investors could view negatively for pipeline replenishment. Article Title

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Bank of America lowered their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Guggenheim raised their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Finally, Barclays began coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Stock Performance

The stock’s 50-day moving average price is $26.99 and its 200-day moving average price is $25.77. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $161.46 billion, a P/E ratio of 20.87 and a beta of 0.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Stance Capital LLC grew its position in shares of Pfizer by 26,746.0% during the fourth quarter. Stance Capital LLC now owns 26,846 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 26,746 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in Pfizer by 27.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,842,275 shares of the biopharmaceutical company’s stock valued at $45,873,000 after purchasing an additional 392,913 shares during the last quarter. World Investment Advisors boosted its stake in Pfizer by 11.2% during the 4th quarter. World Investment Advisors now owns 397,952 shares of the biopharmaceutical company’s stock valued at $9,909,000 after purchasing an additional 40,239 shares during the period. Nalls Sherbakoff Group LLC bought a new position in Pfizer in the 4th quarter worth about $92,000. Finally, DUTCH ASSET Corp acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $237,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.